Al Hayek Ayman Abdullah, Alwin Robert Asirvatham, Al Saeed Abdulghani H, Al Dawish Mohamed Abdulaziz
Department of Endocrinology and Diabetes, Diabetes Treatment Center, Prince Sultan Military Medical City, Riyadh, Saudi Arabia.
Clin Med Insights Endocrinol Diabetes. 2022 May 18;15:11795514221098415. doi: 10.1177/11795514221098415. eCollection 2022.
To analyze patient-reported satisfaction and clinical effectiveness of concentrated insulin glargine 300 U/mL (Gla-300) among patients with type 1 diabetes (T1D) using a flash glucose monitoring (FGM) system.
This comparative study was conducted among 86 patients with T1D (aged 14-40 years), who were treated with Glargine 100 U/mL (Gla-100) and switched to Gla-300 at day 1 (baseline). The following data were collected from each patient: demographic information, clinical parameters, and glycemic control markers. All patients completed the Diabetes Treatment Satisfaction Questionnaire (Arabic version), first at baseline and then after 12 weeks. A comparison was done for all the data recorded at baseline (on Gla-100) and after 12 weeks (on Gla-300) and subjected to analysis.
Compared to patients treated with Gla-100, significant improvements were observed in the Gla-300 group, in terms of the ambulatory glucose profile (AGP) markers, such as percentage of time spent within the target range of the glucose levels (70-180 mg/dL) ( = .037), percentage which fell below the target (<70 mg/dL) ( = .027), and percentage of time spent (<54 mg/dL) ( = .043). Compared to Gla-100, patients treated with Gla-300 experienced significant improvements in the current treatment satisfactions ( = .047), convenient finding treatment recently ( = .034), and flexible finding treatment recently ( = .041), recommend the current treatment ( = .042) and satisfied to continue the current treatment ( = .035).
Compared to the patients on Gla-100, patients treated with Gla-300 exhibited significant improvements in the AGP markers and degree of treatment satisfaction.
使用动态葡萄糖监测（FGM）系统分析1型糖尿病（T1D）患者中患者报告的甘精胰岛素300 U/mL（Gla-300）的满意度和临床疗效。
本比较研究在86例T1D患者（年龄14 - 40岁）中进行，这些患者最初接受甘精胰岛素100 U/mL（Gla-100）治疗，并于第1天（基线）换用Gla-300。收集每位患者的以下数据：人口统计学信息、临床参数和血糖控制指标。所有患者首先在基线时，然后在12周后完成糖尿病治疗满意度问卷（阿拉伯语版）。对在基线（使用Gla-100）和12周后（使用Gla-300）记录的所有数据进行比较并进行分析。
与接受Gla-100治疗的患者相比，Gla-300组在动态葡萄糖谱（AGP）指标方面有显著改善，如血糖水平在目标范围内（70 - 180 mg/dL）的时间百分比（P = 0.037）、低于目标值（<70 mg/dL）的百分比（P = 0.027）以及低于54 mg/dL的时间百分比（P = 0.043）。与Gla-100相比，接受Gla-300治疗的患者在当前治疗满意度（P = 0.047）、近期方便找到治疗方法（P = 0.034）、近期灵活找到治疗方法（P = 0.041）、推荐当前治疗（P = 0.042）以及对继续当前治疗感到满意（P = 0.035）方面有显著改善。
与使用Gla-100的患者相比，接受Gla-300治疗的患者在AGP指标和治疗满意度方面有显著改善。
